• Explore /
  • Poster
  • / Safety assessment of niraparib individualized starting dose in patients with platinum-sensitive recurrent ovarian cancer: A randomized, double-blind, placebo-controlled, phase III NORA trial.

Safety assessment of niraparib individualized starting dose in patients with platinum-sensitive recurrent ovarian cancer: A randomized, double-blind, placebo-controlled, phase III NORA trial.

Abstract Video & Slides Poster

Authors

null

Jing Wang

Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China

Jing Wang , Xiaohua Wu , Jianqing Zhu , Rutie Yin , Jiaxin Yang , Qidan Huang , Lingying Wu , Ziling Liu , Yunong Gao , Danbo Wang , Ge Lou , Hongying Yang , Qi Zhou , Beihua Kong , Yi Huang , Lipai Chen , Guiling Li , Ruifang An , Tao Tan , Juan Dong

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT03705156

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 5535)

DOI

10.1200/JCO.2021.39.15_suppl.5535

Abstract #

5535

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Ursula Matulonis

First Author: Carol Aghajanian

First Author: Lingying Wu

First Author: Ingo K. Mellinghoff